Viral Resistance Analyses From the Remdesivir Phase 3 Adaptive COVID-19 Treatment Trial-1 (ACTT-1)
The Journal of Infectious Diseases · 02.11.2023 · 228 (9) · 1263-1273
DOI: 10.1093/infdis/jiad270 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Infectious Diseases, online erschienen am 19.07.2023. Verfasst von Charlotte Hedskog und 13 weiteren Autor:innen. Beteiligte Einrichtung: Gilead Sciences, Inc, Foster City, California, USA. Hauptthemen laut MEDLINE: COVID-19. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIAID NIH HHS, Gilead Sciences, Inc, National Institute for Allergy and Infectious Diseases.
Abstract (Originalsprache)
Background
Remdesivir is approved for treatment of coronavirus disease 2019 (COVID-19) in nonhospitalized and hospitalized adult and pediatric patients. Here we present severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) resistance analyses from the phase 3 ACTT-1 randomized placebo-controlled trial conducted in adult participants hospitalized with COVID-19.
Methods
Swab samples were collected at baseline and longitudinally through day 29. SARS-CoV-2 genomes were sequenced using next-generation sequencing. Phenotypic analysis was conducted directly on participant virus isolates and/or using SARS-CoV-2 subgenomic replicons expressing mutations identified in the Nsp12 target gene.
Results
Among participants with both baseline and postbaseline sequencing data, emergent Nsp12 substitutions were observed in 12 of 31 (38.7%) and 12 of 30 (40.0%) participants in the remdesivir and placebo arms, respectively. No emergent Nsp12 substitutions in the remdesivir arm were observed in more than 1 participant. Phenotyping showed low to no change in susceptibility to remdesivir relative to wild-type Nsp12 reference for the substitutions tested: A16V (0.8-fold change in EC50), P323L + V792I (2.2-fold), C799F (2.5-fold), K59N (1.0-fold), and K59N + V792I (3.4-fold).
Conclusions
The similar rate of emerging Nsp12 substitutions in the remdesivir and placebo arms and the minimal change in remdesivir susceptibility among tested substitutions support a high barrier to remdesivir resistance development in COVID-19 patients. Clinical Trials Registration. NCT04280705.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Gilead Sciences, Inc, Foster City, California, USA.
- Center for Innate Immunity and Immune Disease, Department of Immunology, University of Washington, Seattle, Washington, USA.
- Fred Hutchinson Cancer Center, Seattle, Washington, USA.
Förderung
- NIAID NIH HHS
- Gilead Sciences, Inc
- National Institute for Allergy and Infectious Diseases
- National Institutes of Health
Zitieren
APA
Hedskog, C., Rodriguez, L., Roychoudhury, P., Huang, M. L., Jerome, K. R., Hao, L., Ireton, R. C., Li, J., Perry, J. K., Han, D., Camus, G., Greninger, A. L., Gale, M., & Porter, D. P. (2023). Viral Resistance Analyses From the Remdesivir Phase 3 Adaptive COVID-19 Treatment Trial-1 (ACTT-1). The Journal of Infectious Diseases, 228(9), 1263-1273. https://doi.org/10.1093/infdis/jiad270
Vancouver
Hedskog C, Rodriguez L, Roychoudhury P, Huang ML, Jerome KR, Hao L, et al. Viral Resistance Analyses From the Remdesivir Phase 3 Adaptive COVID-19 Treatment Trial-1 (ACTT-1). The Journal of Infectious Diseases. 2023;228(9):1263-1273. doi:10.1093/infdis/jiad270
BibTeX
@article{Hedskog2023,
author = {Hedskog, Charlotte and Rodriguez, Lauren and Roychoudhury, Pavitra and Huang, Meei-Li and Jerome, Keith R and Hao, Linhui and Ireton, Renee C and Li, Jiani and Perry, Jason K and Han, Dong and Camus, Gregory and Greninger, Alexander L and Gale, Michael and Porter, Danielle P},
title = {Viral Resistance Analyses From the Remdesivir Phase 3 Adaptive COVID-19 Treatment Trial-1 (ACTT-1)},
journal = {The Journal of Infectious Diseases},
year = {2023},
volume = {228},
number = {9},
pages = {1263--1273},
doi = {10.1093/infdis/jiad270}
}
EUVIMED